ATE245982T1 - Verwendung von 2-amino-6- trifluoromethoxybenzothiazol zur herstellung eines arzneimittels zur vorbeugung oder behandlung von zerebellumkrankheiten - Google Patents

Verwendung von 2-amino-6- trifluoromethoxybenzothiazol zur herstellung eines arzneimittels zur vorbeugung oder behandlung von zerebellumkrankheiten

Info

Publication number: ATE245982T1
Authority: AT; Austria
Prior art keywords: prevention; treatment; trifluoromethoxybenzothiazole; cerebellum; diseases
Prior art date: 1998-02-06

Application number

AT99901703T

Other languages

English (en)

Inventor

Andrees Bohme

Alain Boireau

Thierry Canton

Assunta Imperato

Original Assignee

Aventis Pharma Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-02-06

Filing date

1999-02-03

Publication date

2003-08-15

1999-02-03 Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa

2003-08-15 Application granted granted Critical

2003-08-15 Publication of ATE245982T1 publication Critical patent/ATE245982T1/de

Links

208000015879 Cerebellar disease Diseases 0.000 title abstract 2
FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 title abstract 2
230000002265 prevention Effects 0.000 title abstract 2
229940126601 medicinal product Drugs 0.000 title 1
206010008025 Cerebellar ataxia Diseases 0.000 abstract 1
229960004181 riluzole Drugs 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Thiazole And Isothizaole Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

AT99901703T 1998-02-06 1999-02-03 Verwendung von 2-amino-6- trifluoromethoxybenzothiazol zur herstellung eines arzneimittels zur vorbeugung oder behandlung von zerebellumkrankheiten ATE245982T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR9801402A FR2774592B1 (fr)	1998-02-06	1998-02-06	Application du 2-amino-6-trifluoromethoxybenzothiazole pour la prevention ou le traitement des dysfonctionnements du cervelet
PCT/FR1999/000230 WO1999039710A1 (fr)	1998-02-06	1999-02-03	Application du 2-amino-6- trifluoromethoxy- benzothiazole pour la prevention ou le traitement des dysfonctionnements du cervelet

Publications (1)

Publication Number	Publication Date
ATE245982T1 true ATE245982T1 (de)	2003-08-15

Family

ID=9522673

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99901703T ATE245982T1 (de)	1998-02-06	1999-02-03	Verwendung von 2-amino-6- trifluoromethoxybenzothiazol zur herstellung eines arzneimittels zur vorbeugung oder behandlung von zerebellumkrankheiten

Country Status (18)

Country	Link
US (1)	US6245791B1 (de)
EP (1)	EP1052989B1 (de)
JP (1)	JP5127092B2 (de)
KR (1)	KR100574378B1 (de)
AT (1)	ATE245982T1 (de)
AU (1)	AU761978B2 (de)
CA (1)	CA2319686C (de)
DE (1)	DE69909970T2 (de)
DK (1)	DK1052989T3 (de)
EA (1)	EA002676B1 (de)
ES (1)	ES2199541T3 (de)
FR (1)	FR2774592B1 (de)
IL (2)	IL137608A0 (de)
NO (1)	NO327819B1 (de)
NZ (1)	NZ506124A (de)
PT (1)	PT1052989E (de)
WO (1)	WO1999039710A1 (de)
ZA (1)	ZA99740B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6872739B1 (en)	1999-06-04	2005-03-29	Vereniging Voor Christelijk Wetenshappelikjk Onderwijs	Use of riluzole for the treatment of multiple sclerosis
US10639298B2 (en) *	2015-03-03	2020-05-05	Biohaven Therapeutics Ltd.	Prodrugs of riluzole and their method of use
MD3706739T2 (ro) *	2017-11-12	2025-02-28	Biohaven Therapeutics Ltd	Utilizarea promedicamentelor de riluzol pentru tratarea ataxiei
US12364687B2 (en) *	2018-05-27	2025-07-22	Biohaven Therapeutics Ltd.	Use of riluzole oral disintegrating tablets for treating diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2043070T3 (es) *	1988-12-15	1993-12-16	Rhone Poulenc Sante	Procedimiento para la preparacion de derivados de la benzotiazolamina-2.
FR2700117B1 (fr) *	1993-01-07	1995-02-03	Rhone Poulenc Rorer Sa	Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
FR2702148B1 (fr) *	1993-03-05	1995-04-07	Rhone Poulenc Rorer Sa	Application d'anticonvulsivants dans le traitement du neuro-sida.
FR2714828B1 (fr) *	1994-01-12	1996-02-02	Rhone Poulenc Rorer Sa	Application du riluzole dans le traitement des maladies mitochondriales.
FR2726271B1 (fr) *	1994-10-26	1996-12-06	Rhone Poulenc Rorer Sa	Derives de 6-polyfluoroalcoxy-2-aminobenzothiazole

1998
- 1998-02-06 FR FR9801402A patent/FR2774592B1/fr not_active Expired - Fee Related
1999
- 1999-01-29 ZA ZA9900740A patent/ZA99740B/xx unknown
- 1999-02-03 KR KR1020007008545A patent/KR100574378B1/ko not_active Expired - Fee Related
- 1999-02-03 IL IL13760899A patent/IL137608A0/xx active IP Right Grant
- 1999-02-03 EP EP99901703A patent/EP1052989B1/de not_active Expired - Lifetime
- 1999-02-03 ES ES99901703T patent/ES2199541T3/es not_active Expired - Lifetime
- 1999-02-03 JP JP2000530209A patent/JP5127092B2/ja not_active Expired - Lifetime
- 1999-02-03 DE DE69909970T patent/DE69909970T2/de not_active Expired - Lifetime
- 1999-02-03 EA EA200000816A patent/EA002676B1/ru not_active IP Right Cessation
- 1999-02-03 PT PT99901703T patent/PT1052989E/pt unknown
- 1999-02-03 CA CA002319686A patent/CA2319686C/fr not_active Expired - Lifetime
- 1999-02-03 AU AU21711/99A patent/AU761978B2/en not_active Expired
- 1999-02-03 WO PCT/FR1999/000230 patent/WO1999039710A1/fr not_active Ceased
- 1999-02-03 DK DK99901703T patent/DK1052989T3/da active
- 1999-02-03 NZ NZ506124A patent/NZ506124A/en not_active IP Right Cessation
- 1999-02-03 AT AT99901703T patent/ATE245982T1/de active
2000
- 2000-07-24 NO NO20003785A patent/NO327819B1/no not_active IP Right Cessation
- 2000-07-31 IL IL137608A patent/IL137608A/en not_active IP Right Cessation
- 2000-08-03 US US09/631,798 patent/US6245791B1/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CA2319686A1 (fr)	1999-08-12
NO327819B1 (no)	2009-09-28
ES2199541T3 (es)	2004-02-16
FR2774592A1 (fr)	1999-08-13
IL137608A0 (en)	2001-07-24
KR20010040671A (ko)	2001-05-15
WO1999039710A1 (fr)	1999-08-12
NZ506124A (en)	2003-07-25
AU761978B2 (en)	2003-06-12
JP5127092B2 (ja)	2013-01-23
DE69909970T2 (de)	2004-05-27
PT1052989E (pt)	2003-12-31
DK1052989T3 (da)	2003-11-17
NO20003785D0 (no)	2000-07-24
NO20003785L (no)	2000-07-24
DE69909970D1 (de)	2003-09-04
FR2774592B1 (fr)	2000-03-17
US6245791B1 (en)	2001-06-12
CA2319686C (fr)	2009-06-23
AU2171199A (en)	1999-08-23
ZA99740B (en)	1999-08-02
EP1052989B1 (de)	2003-07-30
IL137608A (en)	2006-09-05
KR100574378B1 (ko)	2006-04-26
EA002676B1 (ru)	2002-08-29
JP2002502819A (ja)	2002-01-29
EP1052989A1 (de)	2000-11-22
EA200000816A1 (ru)	2001-02-26

Similar Documents

Publication	Publication Date	Title
TW200420550A (en)	2004-10-16	Thiazole compounds for the treatment of neurodegenerative disorders
GB0225475D0 (en)	2002-12-11	Therapeutic agents
ES2282685T3 (es)	2007-10-16	Derivados de hidroxietilamina para el tratamiento de la enfermedad de alzheimer.
MXPA04003245A (es)	2004-08-11	Hidroxipropilaminas.
TW200505418A (en)	2005-02-16	Phenacyl 2-hydroxy-3-diaminoalkanes
TW200505828A (en)	2005-02-16	Substituted ureas and carbamates useful in the treatment of alzheimer's disease
ES2189357T3 (es)	2003-07-01	Compustos isocromano y procedimiento para su produccion.
ATE335487T1 (de)	2006-09-15	Verwendung von pyridazino 4,5-(b)ö-indole-1- acetamide derivaten zur herstellung eines arzneimittels zur behandlung von durch periphere benzodiazepinrezeptoren-störungen verursachte krankheiten
WO2006026204A3 (en)	2006-07-27	Novel gamma-lactams as beta-secretase inhibitors
DE69909970D1 (de)	2003-09-04	Verwendung von 2-amino-6-trifluoromethoxybenzothiazol zur herstellung eines arzneimittels zur vorbeugung oder behandlung von zerebellumkrankheiten
ATE247956T1 (de)	2003-09-15	Verwendung von modafinil zur herstellung eines arzneimittels zur behandlung von vigilanzstörungen im zusammenhang mit myopathien
ATE437855T1 (de)	2009-08-15	(4,5,6,7-tetrahydro-1h-indol-7- yl)essigsäurederivate zur behandlung von alzheimer-krankheit
ATE492285T1 (de)	2011-01-15	Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis
ATE257702T1 (de)	2004-01-15	Verwendung von 2-imidazolyl-substituierten carbinolen zur herstellung eines medikaments zur behandlung oder prophylaxe von durch ischämischen zuständen bewirkten krankheiten
DE60219680D1 (de)	2007-05-31	Amin-1,2- und -1,3-diolverbindungen und deren verwendung zur behandlung von alzheimer-krankheit
ATE263565T1 (de)	2004-04-15	Verwendung von 8,9-dehydroestron zur herstellung eines arzneimittels zur behandlung von durch freie radikale verursachte krankheiten
PT1183046E (pt)	2003-12-31	Derivado de aminotetralina para a terapia de doencas cardiovasculares
ATE192650T1 (de)	2000-05-15	Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit
ATE324111T1 (de)	2006-05-15	Verwendung von 2-amino-3,4-dihydro-chinazolinen zur herstellung eines medikaments zur behandlung oder prophylaxe von ischämischen zuständen
DE69610045D1 (de)	2000-10-05	Verwendung eines Rohpflanzenextraktes zur Herstellung eines Arzneimittels zur Behandlung von HIV-Infektionen
ATE186640T1 (de)	1999-12-15	Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung neurogenerativer erkrankungen
ATE350034T1 (de)	2007-01-15	Verwendung von epothilone zur behandlung hyperparathyreoidismus
DE60216090D1 (de)	2006-12-28	Verwendung von l-acetylcarnitin zur herstellung eines medikaments zur behandlung von anhedonia
ATE201993T1 (de)	2001-06-15	Verwendung von olanzapine zur herstellung eines arzneimittels zur behandlung der zerebralen fokalen ischämie
DE60008111D1 (de)	2004-03-11	Verwendung von beta-naphtaquinon derivaten zur herstellung eines arzneimittels mit einem hemmenden effekt auf die glutamatfreisetzung durch das gehirn

Legal Events

Date

Code

Title

Description

2003-12-15

UEP

Publication of translation of european patent specification

Ref document number: 1052989

Country of ref document: EP